IPO News Archive

Supernus Pharmaceuticals prices IPO at $5, raising $50 million

5/1/12


Supernus Pharmaceuticals, a former Shire sub developing improved drug formulations for epilepsy and ADHD, raised $50 million on Monday by offering 10 million shares at $5. The company had originally filed to offer 5.8 million shares at a range of $12 to $14 before filing an amendment last Friday revising deal terms to 11 million shares at an estimated listing price of $5. Supernus Pharmaceuticals plans to list on the NASDAQ under the symbol SUPN. Citi acted as lead manager on the deal.
Keywords/Tickers: SUPN
Related Links: Recently Priced IPOs
Source: www.RenaissanceCapital.com
blog comments powered by Disqus
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the Global IPO Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in Global IPO Fund
About Fund Prospectus Invest